24th Feb 2021 13:52
Renalytix AI PLC - Cardiff, Wales-based clinical diagnostics company - Partners with University of Utah in the US to implement Renalytix AI's in vitro diagnostic platform KidneyIntelX at University of Utah Health, which serves millions of patients across six states. Notes KidneyIntelX is designed for the identification of adults with early-stage chronic kidney disease and diabetes, who are at risk for progressive kidney function decline or kidney failure. Says the partnership aims to improve kidney health and reduce the risk of kidney failure for large scale populations in the earliest stages of kidney disease.
"University of Utah's clinical and translational expertise presents an ideal opportunity to interrupt the devastating and costly effects of progressive chronic kidney disease from its earliest stages to help prevent irreversible late-stage kidney disease and dialysis. This partnership is enabling Renalytix AI to address a major health problem, help build the life sciences sector in Utah and show the economic value of such a robust public private collaboration," says Renalytix AI Chief Executive James McCullough.
Current stock price: 858.00 pence
Year-to-date change: up 76%
By Zoe Wickens; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Renalytix Plc